Loeillot Olivier 4

What Happened

• Olivier Loeillot, Chief Executive Officer of Repligen Corporation (RGEN), received equity awards on March 5, 2026: 24,134 restricted stock units (RSUs) and 25,890 derivative awards (option-type). Both grants are reported as acquisitions at $0.00 (no cash paid at grant).

Key Details

• Transaction date: March 5, 2026. Filing date (Form 4): March 23, 2026 (filed 18 days after the transaction).
• Award amounts and reported values: 24,134 RSUs @ $0.00; 25,890 derivative/option-type awards @ $0.00.
• Vesting schedule:
  • RSUs: Vest in equal annual installments over three years beginning on the first anniversary of the grant (per footnote F1). RSUs will be settled only by delivery of common stock.
  • Derivative awards/options: One-third vests and becomes exercisable each year on March 5, 2027, 2028 and 2029 (per footnote F2).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: The Form 4 was filed well after the standard two-business-day deadline for insiders — the late filing may be noted on the Form 4 and is relevant for disclosure timeliness.

Context

• These grants are compensation awards (not open-market purchases or sales). RSUs convert to actual shares as they vest; the derivative awards appear to be option-type awards that will vest over three years.
• Awards do not require immediate cash outlay by the insider; they represent future equity potential contingent on vesting and, for options, exercise. They are routine executive compensation and should be interpreted as such rather than a direct market buy/sell signal.